VivoSeq
Oncology

Solid Tumor, Adult

21

Pipeline Programs↗

8

Active Trials↗

14

Companies Involved↗

Solid Tumor, Adult is an emerging landscape with 21 programs across 14 companies. The most active players are AstraZeneca, CytomX Therapeutics, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

6/100

Mech. Concentration

9/100

Completion Rate

50/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

3 programs

Phase 1C

CytomX Therapeutics

2 programs

Phase 1T

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

1 program

Phase 1I

ImmunOs Therapeutics AG

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

16 of 21 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody524%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 88% of 25 pipeline programs.

Analysis

Trial Status

12

clinical trials

Recruiting5 · 42%
Active, not recruiting3 · 25%
Suspended2 · 17%
Completed2 · 17%

Clinical Trials

Trial Activity

12 trials

Proof of Principle Study Evaluating Single Dose Dual Immune Checkpoint Inhibitors to Increase Intra-tumoral T Cells in Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinomas With ARID1A Mutations: ESR-22-22082
Recruiting·UUniversity of California, Irvine·Phase 1·NCT06824363·34 enrolled
An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors
Recruiting·CCytomX Therapeutics·Phase 1·NCT06462794·121 enrolled
An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors
Recruiting·CCytomX Therapeutics·Phase 1·NCT06265688·160 enrolled
A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Recruiting·BBioInvent International AB·Preclinical·NCT04219254·197 enrolled
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)
Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06625775·392 enrolled
A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab
Active, not recruiting·LLinnaeus Therapeutics, Inc.·Preclinical·NCT04130516·200 enrolled
First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers
Active, not recruiting·IiOnctura·Phase 1·NCT04328844·210 enrolled
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Active, not recruiting·EEpicentRx, Inc.·Phase 2·NCT04673942·140 enrolled
A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
Completed·IImmunOs Therapeutics AG·Phase 1·NCT05763004·47 enrolled
SPECT Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 in Solid Tumors Patients
Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 1·NCT05620472·10 enrolled
Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Suspended·WWake Forest University Health Sciences·N/A·NCT03987555·22 enrolled
Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers
Suspended·VVirginia Commonwealth University·Preclinical·NCT03919292·83 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)